Suspension of marketing authorisations of 17-Hydroxyprogesterone caproate (17- OHPC) due to its ineffectiveness in authorised uses Abdul Qadir Safety Alerts July 9, 2025July 18, 2025SafetyAlert 58-Suspension-of-marketing-authorisations-of-17-OHPC-due-to-its-un-effectivenessDownload
Risk of Meningioma with Medroxyprogesterone Acetate. Abdul Qadir Safety Alerts July 9, 2025July 9, 2025 59-Risk-of-meningioma-with-Medroxyprogesterone-AcetateDownload
DRAP’s News Letter June 2025 Abdul Qadir Publications July 1, 2025July 8, 2025 DRAP_NewsLtter_June25Download
